TY  - JOUR
A1  - Wenzel, Mike
A1  - Hardenberg, Jost von
A1  - Welte, Maria-Noemi
A1  - Doryumu, Samuel
A1  - Höh, Robert Benedikt
A1  - Wittler, Clarissa
A1  - Höfner, Thomas
A1  - Kriegmair, Maximilian
A1  - Michel, Maurice Stephan
A1  - Chun, Felix
A1  - Herrmann, Jonas
A1  - Mandel, Philipp
A1  - Westhoff, Niklas Christian
T1  - Monoprophylaxis with cephalosporins for transrectal prostate biopsy after the fluoroquinolone-era: a multi-institutional comparison of severe infectious complications
T2  - Frontiers in oncology
N2  - Background: To compare severe infectious complication rates after transrectal prostate biopsies between cephalosporins and fluoroquinolones for antibiotic monoprophylaxis.
Material and Methods: In the multi-institutional cohort, between November 2014 and July 2020 patients received either cefotaxime (single dose intravenously), cefpodoxime (multiple doses orally) or fluoroquinolones (multiple-doses orally or single dose intravenously) for transrectal prostate biopsy prophylaxis. Data were prospectively acquired and retrospectively analyzed. Severe infectious complications were evaluated within 30 days after biopsy. Logistic regression models predicted biopsy-related infectious complications according to antibiotic prophylaxis, application type and patient- and procedure-related risk factors.
Results: Of 793 patients, 132 (16.6%) received a single dose of intravenous cefotaxime and were compared to 119 (15%) who received multiple doses of oral cefpodoxime and 542 (68.3%) who received fluoroquinolones as monoprophylaxis. The overall incidence of severe infectious complications was 1.0% (n=8). No significant differences were observed between the three compared groups (0.8% vs. 0.8% vs. 1.1%, p=0.9). The overall rate of urosepsis was 0.3% and did not significantly differ between the three compared groups as well.
Conclusion: Monoprophylaxis with third generation cephalosporins was efficient in preventing severe infectious complications after prostate biopsy. Single intravenous dose of cefotaxime and multiday regimen of oral cefpodoxime showed a low incidence of infectious complications <1%. No differences were observed in comparison to fluoroquinolones.
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/61405
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-614058
SN  - 2234-943X
VL  - 11
IS  - art. 684144
SP  - 1
EP  - 7
PB  - Frontiers Media
CY  - Lausanne
ER  -